RBC Capital Maintains Outperform on BioCryst Pharma, Lowers Price Target to $13

Benzinga · 1d ago
RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers the price target from $14 to $13.